TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06976216: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated With Mild to Moderate Alzheimer's Disease (MINDSET 1)

Sponsor: Bristol-Myers Squibb · Phase: PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 586 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$3,305,760

Rescue Site Savings

+$2,203,840

Unlock Full NCT06976216 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06976216 Rescue Dossier →